Sanders Morris Harris LLC Makes New $1.51 Million Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Sanders Morris Harris LLC purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 249,596 shares of the company’s stock, valued at approximately $1,513,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Rubric Capital Management LP grew its position in Amneal Pharmaceuticals by 98.8% during the 4th quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock worth $48,560,000 after purchasing an additional 3,975,500 shares in the last quarter. Phocas Financial Corp. acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $4,339,000. Hillsdale Investment Management Inc. boosted its stake in shares of Amneal Pharmaceuticals by 1,240.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 584,619 shares of the company’s stock valued at $3,549,000 after buying an additional 541,000 shares during the period. Vanguard Group Inc. boosted its stake in shares of Amneal Pharmaceuticals by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock valued at $57,174,000 after buying an additional 412,599 shares during the period. Finally, EAM Investors LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $972,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX traded down $0.10 on Friday, hitting $6.65. 1,604,490 shares of the company were exchanged, compared to its average volume of 1,324,609. The company’s 50 day moving average price is $6.44 and its two-hundred day moving average price is $5.90. Amneal Pharmaceuticals, Inc. has a one year low of $2.29 and a one year high of $7.25. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.97 and a current ratio of 1.65. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -11.87 and a beta of 1.19.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, May 3rd. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $659.19 million for the quarter, compared to the consensus estimate of $623.08 million. Amneal Pharmaceuticals had a negative net margin of 6.76% and a positive return on equity of 234.06%. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.51 earnings per share for the current year.

Wall Street Analyst Weigh In

AMRX has been the subject of a number of research reports. The Goldman Sachs Group lifted their target price on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a “buy” rating in a research note on Monday, May 6th. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Piper Sandler lifted their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Finally, Truist Financial reaffirmed a “buy” rating and issued a $9.00 price objective (up previously from $7.00) on shares of Amneal Pharmaceuticals in a research note on Monday, May 6th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $8.25.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.